Related Experiment Video

Updated: Apr 21, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

11.1K

Eribulin: a new-generation antimicrotubule agent in lung cancer therapy

Eddie Thara1, Barbara J Gitlitz

  • 1Keck School of Medicine, Medical Oncology, Norris Comprehensive Cancer Center, Los Angeles, CA, USA.

Future Oncology (London, England)
|November 12, 2014
PubMed

Insights

Eribulin mesylate shows promise in treating metastatic lung cancer, offering potential efficacy with reduced toxicity compared to traditional microtubule agents. Ongoing trials will further confirm its benefits in this patient population.

Area of Science:

  • Oncology
  • Pharmacology
  • Cell Biology

Background:

  • Microtubule antagonists are vital in metastatic lung cancer treatment.
  • These agents often cause significant toxicities and tumor resistance.
  • Eribulin mesylate is a novel agent with a unique binding site on microtubules.

Purpose of the Study:

  • To evaluate the efficacy and safety of eribulin mesylate in metastatic lung cancer.
  • To explore mechanisms of action beyond microtubule disruption.
  • To assess eribulin's potential as an alternative to current therapies.

Main Methods:

  • Review of Phase II trial data for eribulin mesylate.
  • Analysis of preclinical studies on eribulin's mechanisms.
  • Monitoring of an ongoing Phase III trial in metastatic lung cancer.

Main Results:

  • Eribulin mesylate demonstrated effectiveness across various tumor types in Phase II trials.
  • Potential mechanisms suggest superior efficacy and lower toxicity.
  • Phase III data in breast cancer supports its clinical utility.

Conclusions:

  • Eribulin mesylate presents a promising therapeutic option for metastatic lung cancer.
  • Its unique mechanism may overcome resistance and reduce side effects.
  • Further Phase III results are anticipated to solidify its role in lung cancer treatment.
Keywords:
antimicrotubuleeribulinhalichondrinlung cancertaxanes

More Related Videos

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.8K
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

11.2K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
588
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
3.0K